452 related articles for article (PubMed ID: 29854003)
1. Antisense oligonucleotides in neurological disorders.
Wurster CD; Ludolph AC
Ther Adv Neurol Disord; 2018; 11():1756286418776932. PubMed ID: 29854003
[TBL] [Abstract][Full Text] [Related]
2. Making sense of antisense oligonucleotides: A narrative review.
Goyal N; Narayanaswami P
Muscle Nerve; 2018 Mar; 57(3):356-370. PubMed ID: 29105153
[TBL] [Abstract][Full Text] [Related]
3. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
Holm A; Hansen SN; Klitgaard H; Kauppinen S
RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908
[TBL] [Abstract][Full Text] [Related]
4. Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade.
Cantara S; Simoncelli G; Ricci C
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732027
[TBL] [Abstract][Full Text] [Related]
5. Advances of Antisense Oligonucleotide Technology in the Treatment of Hereditary Neurodegenerative Diseases.
Lin M; Hu X; Chang S; Chang Y; Bian W; Hu R; Wang J; Zhu Q; Qiu J
Evid Based Complement Alternat Med; 2021; 2021():6678422. PubMed ID: 34211575
[TBL] [Abstract][Full Text] [Related]
6. Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology.
Amanat M; Nemeth CL; Fine AS; Leung DG; Fatemi A
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36365206
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for selected neuromuscular and trinucleotide repeat disorders - An insight to subsume South Asia for multicenter clinical trials.
Wijekoon N; Gonawala L; Ratnayake P; Sirisena D; Gunasekara H; Dissanayake A; Senanayake S; Keshavaraj A; Hathout Y; Steinbusch HWM; Mohan C; Dalal A; Hoffman E; D de Silva KR
IBRO Neurosci Rep; 2023 Jun; 14():146-153. PubMed ID: 36819775
[TBL] [Abstract][Full Text] [Related]
8. Antisense therapy in neurology.
Lee JJ; Yokota T
J Pers Med; 2013 Aug; 3(3):144-76. PubMed ID: 25562650
[TBL] [Abstract][Full Text] [Related]
9. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
Monine M; Norris D; Wang Y; Nestorov I
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
[TBL] [Abstract][Full Text] [Related]
10. Antisense Drugs Make Sense for Neurological Diseases.
Bennett CF; Kordasiewicz HB; Cleveland DW
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():831-852. PubMed ID: 33035446
[TBL] [Abstract][Full Text] [Related]
11. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy.
Abreu NJ; Waldrop MA
Pediatr Pulmonol; 2021 Apr; 56(4):710-720. PubMed ID: 32886442
[TBL] [Abstract][Full Text] [Related]
12. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.
Bennett CF; Krainer AR; Cleveland DW
Annu Rev Neurosci; 2019 Jul; 42():385-406. PubMed ID: 31283897
[TBL] [Abstract][Full Text] [Related]
13. Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle.
Vita G; Vita GL; Musumeci O; Rodolico C; Messina S
Neurol Sci; 2019 Apr; 40(4):671-681. PubMed ID: 30805745
[TBL] [Abstract][Full Text] [Related]
14. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion.
Shadid M; Badawi M; Abulrob A
Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1281-1292. PubMed ID: 34643122
[TBL] [Abstract][Full Text] [Related]
16. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic antisense oligonucleotides for movement disorders.
Doxakis E
Med Res Rev; 2021 Sep; 41(5):2656-2688. PubMed ID: 32656818
[TBL] [Abstract][Full Text] [Related]
18. [Gene-specific treatment approaches in muscle diseases].
Lehmann Urban D; Schneider I
Nervenarzt; 2020 Apr; 91(4):318-323. PubMed ID: 32076754
[TBL] [Abstract][Full Text] [Related]
19. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
[TBL] [Abstract][Full Text] [Related]
20. [Antisense therapies for neurological diseases].
Pulst SM
Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
